Effect of Omazumab on intestinal flora in patients with chronic idiopathic urticaria

Effect of Omalizumab on Intestinal Flora in Patients with Chronic Idiopathic Urticaria

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033374

Enrollment

Unknown

Registered

2020-05-30

Start date

2020-07-20

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Idiopathic Urticaria

Interventions

case series:Omalizumab on Intestinal Flora

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 30 cases of chronic idiopathic urticaria were diagnosed clinically.

Exclusion criteria

Exclusion criteria: 1. Those who have not used antibiotics, hormones or immunosuppressants in the past 2 months, only received the treatment of omazumab; 2. Subjects whose serum total IgE or free IgE level is higher than normal; 3. Subjects without active tuberculosis, active hepatitis, inflammatory bowel disease, diabetes, kidney disease, cardiovascular disease, systemic lupus erythematosus and other systemic diseases; 4. 18.5 <= BMI <= 23.9; 5. Except for pregnant and lactating women; 6. In addition to the above criteria, chronic idiopathic urticaria needs to meet the requirements of no other skin diseases except chronic urticaria; 7. The subjects who signed the informed consent were required not to eat yoghurt or cheese for the first week before the specimen was taken.

Design outcomes

Primary

Measure	Time frame
the composition of intestinal flora;	—

Countries

China

Contacts

Public ContactWang Mei

Tianjin First Central Hospital

wmwm2046@sina.com+86 13752180490

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026